These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38669554)

  • 21. Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.
    Zamani G; Hosseinpour S; Ashrafi MR; Mohammadi M; Badv RS; Tavasoli AR; Akbari MG; Bereshneh AH; Malamiri RA; Heidari M
    BMC Neurol; 2022 May; 22(1):162. PubMed ID: 35501714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
    Biggar WD; Skalsky A; McDonald CM
    J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
    Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
    Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Associated with Respiratory Health and Function in Duchenne Muscular Dystrophy: A Systematic Review and Evidence Grading.
    Landfeldt E; Aleman A; Abner S; Zhang R; Werner C; Tomazos I; Lochmüller H; Quinlivan RM
    J Neuromuscul Dis; 2024; 11(1):25-57. PubMed ID: 37980679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids.
    Schiava M; Lofra RM; Bourke JP; Díaz-Manera J; James MK; Elseed MA; Malinova M; Michel-Sodhi J; Moat D; Ghimenton E; Mccallum M; Díaz CFB; Mayhew A; Wong K; Richardson M; Tasca G; Eglon G; Eagle M; Turner C; Heslop E; Straub V; Bettolo CM; Guglieri M
    Eur J Neurol; 2024 Jun; 31(6):e16267. PubMed ID: 38556893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic modifiers of respiratory function in Duchenne muscular dystrophy.
    Bello L; D'Angelo G; Villa M; Fusto A; Vianello S; Merlo B; Sabbatini D; Barp A; Gandossini S; Magri F; Comi GP; Pedemonte M; Tacchetti P; Lanzillotta V; Trucco F; D'Amico A; Bertini E; Astrea G; Politano L; Masson R; Baranello G; Albamonte E; De Mattia E; Rao F; Sansone VA; Previtali S; Messina S; Vita GL; Berardinelli A; Mongini T; Pini A; Pane M; Mercuri E; Vianello A; Bruno C; Hoffman EP; Morgenroth L; Gordish-Dressman H; McDonald CM; ; Pegoraro E
    Ann Clin Transl Neurol; 2020 May; 7(5):786-798. PubMed ID: 32343055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy.
    Barp A; Bello L; Politano L; Melacini P; Calore C; Polo A; Vianello S; Sorarù G; Semplicini C; Pantic B; Taglia A; Picillo E; Magri F; Gorni K; Messina S; Vita GL; Vita G; Comi GP; Ermani M; Calvo V; Angelini C; Hoffman EP; Pegoraro E
    PLoS One; 2015; 10(10):e0141240. PubMed ID: 26513582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.
    Bello L; Kesari A; Gordish-Dressman H; Cnaan A; Morgenroth LP; Punetha J; Duong T; Henricson EK; Pegoraro E; McDonald CM; Hoffman EP;
    Ann Neurol; 2015 Apr; 77(4):684-96. PubMed ID: 25641372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and genetic characteristics of Chinese Duchenne/Becker muscular dystrophy patients with small mutations.
    Gan S; Liu S; Yang H; Wu L
    Front Neurosci; 2022; 16():992546. PubMed ID: 36419457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.
    Flanigan KM; Ceco E; Lamar KM; Kaminoh Y; Dunn DM; Mendell JR; King WM; Pestronk A; Florence JM; Mathews KD; Finkel RS; Swoboda KJ; Gappmaier E; Howard MT; Day JW; McDonald C; McNally EM; Weiss RB;
    Ann Neurol; 2013 Apr; 73(4):481-8. PubMed ID: 23440719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Modifiers and Phenotype of Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
    Pascual-Morena C; Cavero-Redondo I; Saz-Lara A; Sequí-Domínguez I; Lucerón-Lucas-Torres M; Martínez-Vizcaíno V
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
    Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
    Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
    [No Abstract]   [Full Text] [Related]  

  • 34. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.
    Kim S; Campbell KA; Fox DJ; Matthews DJ; Valdez R;
    J Child Neurol; 2015 Sep; 30(10):1275-80. PubMed ID: 25414237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
    McDonald CM; Shieh PB; Abdel-Hamid HZ; Connolly AM; Ciafaloni E; Wagner KR; Goemans N; Mercuri E; Khan N; Koenig E; Malhotra J; Zhang W; Han B; Mendell JR;
    J Neuromuscul Dis; 2021; 8(6):989-1001. PubMed ID: 34120909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-range genomic regulators of THBS1 and LTBP4 modify disease severity in duchenne muscular dystrophy.
    Weiss RB; Vieland VJ; Dunn DM; Kaminoh Y; Flanigan KM;
    Ann Neurol; 2018 Aug; 84(2):234-245. PubMed ID: 30014611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of genetic mutations and loss of ambulation in childhood-onset dystrophinopathy.
    Haber G; Conway KM; Paramsothy P; Roy A; Rogers H; Ling X; Kozauer N; Street N; Romitti PA; Fox DJ; Phan HC; Matthews D; Ciafaloni E; Oleszek J; James KA; Galindo M; Whitehead N; Johnson N; Butterfield RJ; Pandya S; Venkatesh S; Bhattaram VA
    Muscle Nerve; 2021 Feb; 63(2):181-191. PubMed ID: 33150975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy.
    Alfano LN; Charleston JS; Connolly AM; Cripe L; Donoghue C; Dracker R; Dworzak J; Eliopoulos H; Frank DE; Lewis S; Lucas K; Lynch J; Milici AJ; Flynt A; Naughton E; Rodino-Klapac LR; Sahenk Z; Schnell FJ; Young GD; Mendell JR; Lowes LP
    Medicine (Baltimore); 2019 Jun; 98(26):e15858. PubMed ID: 31261494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A; Schaeffer EK; Reilly CW
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.